Summary
48 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 11% this fiscal year.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 2.7% a year over the last 3 years.
- It earns only 3.8 CNY a year on every 100 CNY of invested capital.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.6 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 5.9% a year over 5 years. Over the last 3 years it fell by 2.7% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share fell by 4.1% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 50 CNY
- Research and development 10 CNY
- Sales and administration 32 CNY
- Taxes and other 0.2 CNY
- Net profit 8.1 CNY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 CNY
Out of every 100 CNY of revenue, 8.1 CNY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 44.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.64%
- Paid out of profit
- 20%
- Raised in a row
- 1 year
You receive $0.06 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.